To the Editor We read with interest the article by Choi et al1 recently published in JAMA Oncology. The authors performed a nationwide historical population cohort study involving 24 156 treatment-naive patients with chronic hepatitis B who started treatment with entecavir or tenofovir disoproxil fumarate, comparing the 2 drugs in terms of the risk of hepatocellular carcinoma (HCC) and death or liver transplant. An interesting result was that tenofovir treatment was associated with a significantly lower risk of HCC compared with entecavir treatment.1 After reading this article carefully, we thought that 1 important issue should be discussed.
Zhang H, Zeng W. Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. JAMA Oncol. 2019;5(6):914–915. doi:10.1001/jamaoncol.2019.0641
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.